Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy

Haematologica

Volumn 97, Issue 9, 2012, Pages 1320-1328

  Saif, Muhammad Ameer ^a,b   Bigger, Brian W ^a,b   Brookes, Karen E ^a   Mercer, Jean ^c   Tylee, Karen L ^c   Church, Heather J ^c   Bonney, Denise K ^b   Jones, Simon ^c   Ed Wraith, J ^c   Wynn, Robert F ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Allo antibodies; Enzyme replacement therapy; Hematopoietic stem cell transplantation; Hurler's syndrome; Immune tolerance induction; Mucopolysaccharidosis

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN G; LEVO IDURONIDASE; MANNOSE 6 PHOSPHATE; MELPHALAN; METHOTREXATE; NEUTRALIZING ANTIBODY; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADENOVIRUS INFECTION; ANTIBODY TITER; ARTICLE; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; FEMALE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HEART ARREST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFANT; KIDNEY TUBULE ACIDOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; NEUTROPENIA; PNEUMONIA; PNEUMOTHORAX; PRESCHOOL CHILD; PROTEIN TRANSPORT; VEIN OCCLUSION; VIRAL GASTROENTERITIS; VIRUS REACTIVATION; WESTERN BLOTTING; ADOLESCENT; ADULT; ANIMAL; BLOOD; CROSS-SECTIONAL STUDY; FOLLOW UP; GRAFT VS HOST DISEASE; IMMUNOLOGY; LONGITUDINAL STUDY; MOUSE; MUCOPOLYSACCHARIDOSIS I; MULTIMODALITY CANCER THERAPY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; ENZYME REPLACEMENT THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; INFANT; ISOANTIBODIES; LONGITUDINAL STUDIES; MALE; MICE; MUCOPOLYSACCHARIDOSIS I; PROGNOSIS; YOUNG ADULT;

EID: 84864532141     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.058644     Document Type: Article

References (36)

1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324(21):1464-70.
2. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess. 2006;10(20):iii-iv, ix-113.
3. Ponder KP. Immune response hinders therapy for lysosomal storage diseases. J Clin Invest. 2008;118(8):2686-9.
4. Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90(1):1-11.
5. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229-40.
6. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzymereplacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182-8.
7. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-Liduronidase (laronidase). Pediatrics. 2007; 120 (1):e37-46.
8. Dickson P, Peinovich M, McEntee M, Lester T, Le S, Krieger A, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest. 2008;118(8):2868-76.
9. Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9(10):450-3.
10. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA. 1994;91 (26):12937-41.
11. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99 (1):26-33.
12. de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101(4):338-45.
13. Kakkis E, Lester T, Yang R, Tanaka C, Anand V, Lemontt J, et al. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc Natl Acad Sci USA. 2004;101(3):829-34.
14. Wynn RF, Mercer J, Page J, Carr TF, Jones S, Wraith JE. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr. 2009;154(1):135-9.
15. Stirling JL, Robinson D, Fensom AH, Benson PF, Baker JE. Fluorimetric assay for prenatal detection of Hurler and Scheie homozygotes or heterozygotes. Lancet. 1978;1(8056):147.
16. Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells. Protein Expr Purif. 1994;5(3):225-32.
17. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150 (1):76-85.
18. Wynn RF, Wraith JE, Mercer J, O'Meara A, Tylee K, Thornley M, et al. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr. 2009;154(4):609-11.
19. Church H, Tylee K, Cooper A, Thornley M, Mercer J, Wraith E, et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007;39(4):207-10.
20. Langford-Smith K, Arasaradnam M, Wraith JE, Wynn R, Bigger BW. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol Genet Metab. 2010;99(3):269-74.
21. Langford-Smith KJ, Mercer J, Petty J, Tylee K, Church H, Roberts J, et al. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short-and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis. 2011;34 (2):499-508.
22. Whiteman P. Prenatal diagnosis of mucopolysaccharidoses. Lancet. 1973;1 (7814):1249.
23. Spijker AJ, Poortman J, Thijssen JH, Erkelens DW. Decrease of circulating insulin antibodies in two patients treated with continuous subcutaneous infusion of human insulin (recombinant DNA). Diabetes Care. 1982;5(2):171-4.
24. Yoshioka A, Fukutake K, Takamatsu J, Shirahata A. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol. 2003;78 (5):467-74.
25. Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab. 1999;68(2):268-75.
26. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1-2):1-16.
27. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114(4):e532-5.
28. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by coadministration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol. 2008;152(1): 138-46.
29. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics. 1997;100(6):E11.
30. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003; 88(6):EREP04.
31. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmo protocol update. Haematologica. 2000;85(10):48-50.
32. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16(1):S48-S56.
33. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358(4):353-61.
34. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358(4):362-8.
35. Bigger BW, Siapati EK, Mistry A, Waddington SN, Nivsarkar MS, Jacobs L, et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther. 2006;13(2): 117-26.
36. Douillard-Guilloux G, Richard E, Batista L, Caillaud C. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med. 2009;11(4):279-87.